Greenway Health (GWAY) versus Fluidigm (FLDM) Head-To-Head Analysis
Greenway Health (NYSE: GWAY) and Fluidigm (NASDAQ:FLDM) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.
Insider & Institutional Ownership
78.7% of Fluidigm shares are owned by institutional investors. 4.7% of Fluidigm shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of recent recommendations for Greenway Health and Fluidigm, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Fluidigm has a consensus price target of $9.00, suggesting a potential upside of 56.25%.
Earnings and Valuation
This table compares Greenway Health and Fluidigm’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Fluidigm||$104.45 million||2.13||-$75.98 million||($2.24)||-2.57|
Greenway Health has higher revenue, but lower earnings than Fluidigm. Fluidigm is trading at a lower price-to-earnings ratio than Greenway Health, indicating that it is currently the more affordable of the two stocks.
This table compares Greenway Health and Fluidigm’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
About Greenway Health
Greenway Health LLC is a United States-based company, which provides clinical, financial and administrative solutions for healthcare providers. The Company provides integrated clinically driven revenue cycle management and electronic health record (EHR) solutions. Its suite of solutions and services is PrimeSUITE, which integrates clinical, financial and administrative data in a single database to enable views of patient records and workflow throughout each patient encounter, reduce clinical and administrative errors, and allow for the exchange of data between its customers and the healthcare community. It offers its solutions by offering managed business services, such as clinically-driven revenue cycle and EHR-enabled research services.
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.
Receive News & Ratings for Greenway Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenway Health Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.